DNA encoding members of the IL-1 family, IL-1 delta
IL-1 delta polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing IL-1 delta peptides are polynucleotides in the design of protocols for the treatment of chronic and acute inflammation, arthritis, septicemia, autoimmune diseases (e.g. inflammatory bowel disease, psoriasis), transplant rejection, graft versus host disease, infection, stroke, ischemia, acute respiratory disease syndrome, restenosis, brain injury, AIDS, bone diseases (e.g. osteoporosis), cancer (e.g. lymphoproliferative disorders), atherosclerosis, and Alzheimer's disease, among others, and diagnostic assays for such conditions.
Latest SmithKline Beecham Corporation Patents:
- Apparatus for producing a pharmaceutical product
- Apparatus and method for producing a pharmaceutical product
- Lipoprotein Associated Phospholipase A2, Inhibitors Thereof and Use of the Same in Diagnosis and Therapy
- Apparatus and method for producing or processing a product or sample
- Method for customized dispensing of variable dose drug combination products for individualizing of therapies
Claims
1. An isolated polynucleotide comprising a nucleotide sequence has at least 95% identity over its entire length to a nucleotide sequence encoding the polypeptide of SEQ ID NO: 2, said identity being calculated using FASTA wherein the two sequences are maximally aligned so that highest order match between the sequences is obtained.
2. The isolated polynucleotide of claim 1 comprising a nucleotide sequence encoding the polypeptide of SEQ ID NO: 2.
3. An isolated polynucleotide comprising a nucleotide sequence which has at least 95% identity to SEQ ID NO: 1, said identity being over the entire length of SEQ ID NO: 1 and calculated using FASTA wherein sequences are maximally aligned so that highest order match between the sequences is obtained.
4. The isolated polynucleotide of claim 3 having the nucleotide sequence of SEQ ID NO: 1.
5. The isolated polynucleotide of claim 4 wherein said nucleotide sequence comprises nucleotides 112 to 603 of SEQ ID NO: 1.
6. An isolated polynucleotide which is complementary to the polynucleotide of any one of claims 1, 2, 3, 4, or 5.
7. An expression system comprising a polynucleotide of claim 2 capable of producing a polypeptide comprising an amino acid sequence of SEQ ID NO: 2 when said expression system is present in a compatible host cell.
8. A process for producing a recombinant host cell comprising transforming or transfecting a cell with the expression system of claim 7 such that the host cell, under appropriate culture conditions, produces a polypeptide comprising an amino acid sequence of SEQ ID NO: 2.
9. A recombinant host cell produced by the process of claim 7.
10. A membrane of a recombinant host cell of claim 9 expressing a polypeptide comprising an amino acid sequence of SEQ ID NO: 2.
11. A process for producing a polypeptide comprising culturing the recombinant host cell of claim 9 under conditions sufficient for the production of said polypeptide and recovering the polypeptide from the culture.
- Okamura et al, Nature 378, Nov. 1995, pp. 88-91. Bazan et al Nature 379, Feb. 1996, p. 591. EST #78362.
Type: Grant
Filed: Sep 29, 1997
Date of Patent: Aug 31, 1999
Assignee: SmithKline Beecham Corporation (Philadelphia, PA)
Inventors: Peter Ronald Young (Lawrenceville, NJ), Ian E. James (Ardmore, PA), Janice R. Connor (Fort Washington, PA)
Primary Examiner: Garnette D. Draper
Attorneys: William T. Ratner & Prestia Han, William T. King
Application Number: 8/939,300
International Classification: C12N 1524; C12N 1500;